Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Clinical Trials Regulation

Keeping Track: Allergan Antipsychotic Vraylar Approved; First-Line Imbruvica Claim Submitted

  • Analysis

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

You may also be interested in...



Keeping Track: An RMAT, Two QIDPs, And Some Bad News Too

The latest drug development news and highlights from our FDA Performance Tracker.

Keeping Track: Pfizer’s Zavzpret Brings Nasal Delivery To CGRP Antagonists; Ionis/AZ Advance Antisense Eplontersen In ATTR

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Lessons Still To Learn: Cytokinetics’ Omecamtiv Is Over In The US, But FDA Debriefs Could Inform European Strategy

Cytokinetics will not conduct the new trial in heart failure with reduced ejection fraction (HFrEF) required by the FDA’s complete response letter for omecamtiv mecarbil.

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical Clinical Trials Regulation
Latest Headlines

A Milestone Moment For Pharmacogenomics: US FDA Ready To Drop ‘Voluntary’ Program

Electronic Records: US FDA Updates Guidelines On Use In Clinical Investigations

Device Component Of Intarcia’s Diabetes Treatment ITCA 650 Worries FDA

AAM Departures Lead To Change Of Chair For IGBA

See All
UsernamePublicRestriction

Register

PS057132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By